Nurix Therapeutics, Inc. · NASDAQ:NRIX
Nurix Therapeutics — Investor Presentation (January 2025)
31 slides from Nurix Therapeutics's investor presentation, Jan 13, 2025
Slide 1: Medicines to Outmatch Disease
Medicines to Outmatch Disease Investor Presentation January 13, 2025 Exhibit 99.2
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipa
Slide 3: Key accomplishments in 2024
Key accomplishments in 2024 Another Great Year at Nurix 3 Demonstrated clear clinical proof of concept for BTK degradation with NX-5948 • Completed Phase 1a dose escalation • Demonstrated robust efficacy in CLL and WM with favorable safety profile • Oral presentations at ASH and EHA Established unme
Slide 4: Meeting the needs of patients with breakthrough therapies
Meeting the needs of patients with breakthrough therapies Drug Discovery Pipeline Strategy 4 Clinically validated targets where inhibitors fail to address resistance and scaffolding Unmet medical need where inhibitors are not sufficient to drive efficacy "Undruggable" targets Kinase targets in cance
Slide 5: Establish Degrader-Based Medicines at the Forefront of Patient Care
Establish Degrader-Based Medicines at the Forefront of Patient Care • Degraders act as molecular matchmakers, bringing together two key players: • An E3 ligase (a key part of a cell’s protein degradation machinery) • A disease-causing target protein • This process, called induced proximity, enables
Slide 6: Industry Leading DEL-AI Discovery Engine for TPD and DAC Drug Discovery
Industry Leading DEL-AI Discovery Engine for TPD and DAC Drug Discovery Our DEL-AI discovery engine leverages the combined power of our data-rich DEL capabilities, automated chemistry, and advanced machine learning to accelerate drug discovery 6 TPD, targeted protein degradation; DAC, degrader antib
Slide 7: Nurix Is Advancing a Pipeline of Proprietary and Partnered Programs
Nurix Is Advancing a Pipeline of Proprietary and Partnered Programs in Oncology and Inflammation & Immunology 7 Program Target Modality Therapeutic area Discovery IND-Enabling Phase 1A Phase 1B/2 NX-5948 BTK Degrader B-cell malignancies NX-2127 BTK-IKZF Degrader B-cell malignancies NX-1607 CBL-B Inh
Slide 8: BTK Targeted Agents Are a Major Value Driver Across Biotech and Pharma
• Next generation BTK inhibitors are currently taking market share from Imbruvica • All BTK inhibitors share resistance mutation vulnerabilities Current market for BTK inhibitors annualizing at over $10 billion BTK Targeted Agents Are a Major Value Driver Across Biotech and Pharma 8 0 1000 2000 3000
Slide 9: Why Do We Need BTK Degraders?
Why Do We Need BTK Degraders? 9 • BTK degraders address BTK scaffolding function • BTK degraders have demonstrated clinical activity in difficult to treat B-cell malignancies • BTK degraders have the potential to address significant unmet needs in autoimmune and inflammatory disorders • BTK degrader
Slide 10: NX-5948-301 Trial Design
NX-5948-301 Trial Design Phase 1a/b Trial in Adults with Relapsed/Refractory B-cell Malignancies CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; NHL, non-Hodgkin’s lymphoma; WM, Waldenström macroglobulinemia; BTKi, BTK inhibitor; BCL2i, Bcl-2 inhibitor; QD, once daily Phase 1a do
Slide 11: Heavily Pre-Treated Patients With a High Prevalence of Baseline Mutations
Baseline disease characteristics Heavily Pre-Treated Patients With a High Prevalence of Baseline Mutations aBaseline disease characteristics in CLL cohort were comparable to those in the overall population; bPatients could have received multiple prior treatments; cAll patients who received ncBTKi ha
Slide 12: NX-5948 Degrades Wild-Type and Mutated BTK
NX-5948 degrades gatekeeper, kinase-proficient and kinase-dead BTK mutations NX-5948 Degrades Wild-Type and Mutated BTK Reference 1. Montoya et al. Science 2024;383 Patients with CLL/SLL (n=57)c Baseline mutation status, n (%) BTK mutations1,a,b 22 (38.6) C481S 12 (21.1) C481R 2 (3.5) L528W 4 (7.0)
Slide 13: Response Rate Deepens with Longer Time on Treatment
NX-5948 overall response assessment Response Rate Deepens with Longer Time on Treatment CLL, chronic lymphocytic leukemia; CR, complete response; iwCLL, International Workshop on CLL; ORR, objective response rate; PD, progressive disease; PR, partial response; PR-L, partial response with rebound lym
Slide 14: Clinical Activity in CLL Patients Including Those with Baseline Mutations and CNS Involvement
Clinical Activity in CLL Patients Including Those with Baseline Mutations and CNS Involvement ATM, Ataxia-telangiectasia mutated; BTK, Bruton’s tyrosine kinase; BTKi, BTK inhibitor; CLL, chronic lymphocytic leukemia; CNS, central nervous system; iwCLL, International Workshop on CLL; NOTCH1, neurolog
Slide 15: NX-5948 Safety Profile
TEAEs in ≥10% of overall population or Grade ≥3 TEAEs or SAEs in >1 patient NX-5948 Safety Profile aPurpura/contusion includes episodes of contusion or purpura; bFatigue was transient; cAggregate of ‘thrombocytopenia’ and ‘platelet count decreased’; dAggregate of ‘rash’ and ‘rash maculopapular’ and
Slide 16: High Preliminary Overall Response in Patients with Waldenström Macroglobulinemia
Preliminary efficacy presented at the International Workshop on Waldenström Macroglobulinemia NX-5948 High Preliminary Overall Response in Patients with Waldenström Macroglobulinemia CR, complete response; MR minor response; ORR, objective response rate; PD, progressive disease; PR, partial response
Slide 17: Rapid and Durable Responses to NX-5948 in Waldenström Macroglobulinemia
Rapid and Durable Responses to NX-5948 in Patients with Waldenström Macroglobulinemia Data cutoff: 10 Oct 2024 Select prior therapies Select mutations BTKi BCL2i Pirto CXCR4 MYD88 *Ineligible, identified post 1st dose #Transformed to DLBCL * # WM disease-evaluable patients n=9 ORR, % 77.8 Best respo
Slide 18: NX-5948 Regulatory Milestones
NX-5948 Regulatory Milestones 18 CLL WM Advancing NX-5948 program globally in CLL and WM • U.S. Fast Track Designation from the FDA in January 2024 • Type B End of Phase 1 meeting held with the FDA, key takeaways: • Reviewed dose levels of 200 mg QD and 600 mg QD in the context of Project Optimus •
Slide 19: Accelerating Development of NX-5948 in CLL with First Pivotal Study in 2025
Nurix Is Accelerating Development of NX-5948 in CLL with First Pivotal Study To Be Initiated in 2025 • Clear demonstration of clinical activity in difficult to treat CLL population • Phase 1b cohorts enrolling rapidly with post-BTKi/post-BCL2i CLL patients randomized between 200mg QD and 600mg QD •
Slide 20: Inflammation & Immunology
Inflammation & Immunology 20 Leveraging our expertise in B- and T-cell biology, Nurix is building a pipeline of innovative degrader drugs to address the unmet medical need for patients living with inflammation and autoimmune disorders
Slide 21: Advancing NX-5948 in Immunology and Inflammation
Advancing NX-5948 in Immunology and Inflammation The genetics of BTK are compelling: highly specific with potent biology • Human and mouse knockouts are associated with reduced immune function yet have otherwise normal physiology Positive clinical experience • BTK inhibitors have shown positive clin
Slide 22: Potent Suppression of Myeloid Cell Stimulation
Potent Suppression of Myeloid Cell Stimulation NX-5948 More Potently Suppresses Activation of Stimulated B Cells and Myeloid Cells Compared to a Range of BTK Inhibitors 22 Potent Suppression of B Cell Stimulation 0.001 0.01 0.1 1 10 100 1000 -75 -50 -25 0 25 50 75 100 125 Compound (nM) N or m al iz
Slide 23: NX-5948 Has the Right Clinical Profile for Oncology and I&I
Wide dose range produces robust BTK degradation NX-5948 Has the Right Clinical Profile To Address Unmet Clinical Needs in Both Oncology and I&I 23 Elimination of BTK’s scaffolding function Demonstrated ability to cross the blood-brain barrier Favorable safety profile in oncology clinical trials 0 20
Slide 24: Systematic Approach To Expand NX-5948 Across I&I Indications
Nurix’s Systematic Approach To Expand Development of NX-5948 Across Multiple I&I Indications Next Steps: 1. Plan to open a new Phase 1b cohort for patients with CLL and associated autoimmune hemolytic anemia in H1 2025 2. Plan non-malignant hematology IND in 2025 for autoimmune cytopenias (e.g., wAI
Slide 25: IRAK4 Degrader NX-0479/GS-6791
IRAK4 Degrader NX-0479/GS-6791 for the Potential Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases Source: Teng et al., ACR 2024, November 2024 .25 IND anticipated in 2025; Nurix has a co-development and 50/50 profit share option in the United States • IRAK4 is a master regulator of
Slide 26: STAT6 Degrader for Th2-Mediated Inflammatory Disorders
STAT6 Degrader for the Potential Treatment of Th2-Mediated Inflammatory Disorders Such as Allergies, Asthma, and Eczema JAK, Janus kinase; pSTAT, phosphorylated Janus kinase26 • Signal Transducer and Activator of Transcription 6 (STAT6) is a key transcription factor in the JAK/STAT signaling pathway
Slide 27: Degrader Antibody Conjugates (DACs)
27 DACs represent the next evolution in targeted protein degradation, combining the highly potent and catalytic activity of degraders with the cell and tissue specificity of antibodies Degrader Antibody Conjugates (DACs)
Slide 28: Advancing a New Therapeutic Class
Advancing a New Therapeutic Class • DACs combine the catalytic activity of a degrader with the specificity of an antibody • DACs represent the next generation of antibody drug conjugates (ADCs) Degrader Antibody Conjugates (DACs) 28 Seagen* Deal Terms • $60 million upfront cash payment • $3.4 billio
Slide 29: DACs Provide Exquisite Selectivity
DACs Provide Exquisite Selectivity 29 ADCs DegradersDACs Antigen provides cell and tissue selectivity Degrader target and ligase expression provide cell and tissue selectivity DAC provides multi-layer selectivity DACs Degrade Target Protein Only in Cells Expressing a Select Antigen 0.001 0.01 0.1 1
Slide 30: Well Funded to Execute on Our Strategy
Estimated $609.6 million in cash and investments at fiscal year-end 2024, November 30, 2024* Well Funded to Execute on Our Strategy Key initiatives for 2025 • Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of patients with chronic lym
Slide 31: Thank you
NURIX Thank you
Nurix Therapeutics — Investor Presentation (January 2025) on 6ix